Navigation Links
High Lipoprotein Levels Can Cause Heart Disease
Date:12/23/2009

Study shows it could be a new target for prevention and treatment

WEDNESDAY, Dec. 23 (HealthDay News) -- A genetic study proves that high blood levels of the fat-carrying molecule called lipoprotein(a) can cause heart disease.

"The case for lipoprotein(a) as a direct cause of coronary artery disease is now firm," said Martin Farrall, a professor of cardiovascular genetics at the University of Oxford in England and senior author of a report in the Dec. 24 issue of the New England Journal of Medicine.

Elevated blood levels of LPA, as it is often abbreviated, have been linked to an increased risk of heart disease and other cardiovascular problems for decades, but the evidence has not been definitive. So while an elevated low-density lipoprotein (LDL) cholesterol level remains the most clearly established indicator of coronary risk, "our paper, by genetic research, shows that LPA plays an important role as well," Farrall said.

"Our results will not perhaps surprise some researchers, but the scale of this project and confidence in our results mean that we can move forward to study the details of LPA and coronary risk," he added.

It is a pivotal finding, said Dr. Sekar Kathiresan, director of preventive cardiology at Massachusetts General Hospital, who wrote an accompanying editorial. "Many things in medicine are associated with an increased risk of heart attack. Almost all of these associations are not of a causal nature. This brings LPA into the domain of causal factors. And if it is causal, that gives hope that reducing it can reduce the risk of heart attack," he said. "

"We are now honing in on a potential therapeutic target," Kathiresan stated.

LPA is a member of the family of molecules that carry LDL cholesterol, the "bad" kind that clogs arteries, in the blood. The most common such molecule is lipoprotein(b), which consists of LDL with one protein attached. LPA is different because it has an additional protein attached.

The study done by Farrall and his colleagues looked in exquisite detail at the genetic makeup of 3,145 people with coronary artery disease and 3,352 free of coronary disease. The study of more than 48,000 variants of 2,100 genes found that two variants affecting LPA levels were strongly associated with coronary disease.

"We speculate and anticipate that our finding may carry over to other cardiovascular diseases, such as some kinds of stroke," Farrall said.

The reason for the harmful effects of LPA is unknown, he said. "A number of speculative mechanisms have been proposed," Farrall said. "Our study doesn't help resolve those."

One immediate impact of the research could be widened use of a blood test for LPA, which has been available for years, Kathiresan said. "This kind of study shows that people who carry a genetically determined high level of LPA have an increased risk, and this will likely increase enthusiasm for measuring LPA blood levels, particularly for people who have heart disease at an early age or have a strong family history of heart disease," he said.

And while at least one available drug, niacin, is known to reduce LPA levels to some extent, "we need a drug that selectively reduces LPA," Kathiresan said. "There is some effort to do that."

A major controlled trial will be needed to show that an LPA-lowering drug reduces the incidence of coronary disease, he added.

One odd sidelight is that while participants in the new study -- and most previous trials -- were white Europeans, elevated LPA levels are more common among people from Africa and southern Asia, Kathiresan noted. Studies of those populations are needed, he stressed.

More information

An introduction to the world of lipoproteins is provided by the American Heart Association.



SOURCES: Martin Farrall, professor, cardiovascular genetics, University of Oxford, England; Sekar Kathiresan, director, preventive cardiology, Massachusetts General Hospital, and assistant professor, medicine, Harvard Medical School, Boston; Dec. 24, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
2. Lipoprotein Levels May Predict Womens Hypertension Risk
3. Adult offspring of parents with PTSD have lower cortisol levels
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Screening Proposed for Childhood Cholesterol Levels
6. Womens Folic Acid Levels Improving
7. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
8. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
9. School, family and community involvement are all needed to increase the activity levels of adolescen
10. High HDL Levels Protect Heart Health
11. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... In an ... today GrassrootsHealth, a public health promotion and research organization, declared May as “National ... society, and other shifts in cultural behavior over the past several decades, Americans ...
(Date:5/4/2016)... ... May 04, 2016 , ... ProList is a set of ... . With ProList, editors can easily create lists for presentations, youtube productions, and ... bullet points. ProList is the perfect complement to presentation style videos. , ProList ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... engineer of patented products, announces the Everlasting Glove, a sports invention that aids ... Athletic and Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, ... patent for its innovative Secure Messaging platform, which includes secure, private messaging, large ... patent extends Cirius’s portfolio of patents around innovative features for securing, tracking, and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... BRIDGEWATER, New Jersey , May 4, 2016 /PRNewswire/ ... today its successful completion of an alternative public offering ... its wholly owned operating company, Valeritas, Inc. and a ... unregistered common stock at $5.00 per share. ... completed on May 3, 2016, Valeritas Holdings, Inc. will ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: